RLX Technology Q3 2024 Revenue Up 20.6% to $104M Net Profit $35.62M

Nov.15.2024
RLX Technology Q3 2024 Revenue Up 20.6% to $104M Net Profit $35.62M
RLX Technology reported Q3 2024 net revenue of $104 million, a 20.6% quarter-over-quarter increase, and net profit of $35.62 million. The company attributed the growth primarily to its international expansion.

On November 15th, RELX Technology (RLX Technology Inc.) (NYSE: RLX) released its unaudited financial report for the third quarter of 2024.

 

According to the financial report, the net revenue for the third quarter of 2024 was $104.12 million, marking a 20.6% increase quarter-over-quarter and a 51.6% increase year-over-year.  

 

Under non-US GAAP, the adjusted net profit for the third quarter was $35.62 million, up 22.9% from the previous quarter and 30.0% year-over-year.  

 

The financial highlights for the third quarter of 2024 are as follows:  

 

  • Net Revenue: $104.12 million, a 20.6% increase quarter-over-quarter and a 51.6% increase year-over-year, driven primarily by the company's international expansion.  
  • Gross Profit: $28.77 million.  
  • Adjusted Net Profit: $35.62 million under non-US Generally Accepted Accounting Principles.  
  • Cash and Investments: As of September 30, 2024, RLX Technology held $2.10 billion in total cash, cash equivalents, restricted cash, short-term bank deposits, short-term investments, long-term bank deposits, and long-term investment securities.  

 

RELX Technology founder, chairman, and CEO Wang Ying said: "The company delivered strong performance once again in the third quarter, showcasing its ability to thrive amid rapidly evolving market trends and regulatory changes."  

 

"Our efficient and adaptable localization strategy has positioned us as market leaders in several countries. By working closely with local distributors and retailers, we have achieved a high level of product-market alignment."  

 

"Built on a foundation of high-quality and reliable pod products, we now offer a broader portfolio, including a diverse range of disposable and open-system products. These innovations have earned the trust of adult smokers worldwide."  

 

"As a trusted e-cigarette brand for adult smokers, we remain dedicated to developing innovative, high-quality products that align with market trends and comply with regulatory standards. Our goal is to meet the needs of global users while driving sustainable long-term growth for the company. "

 

RELX Technology's CFO, Lu Chao, said: "The company's net income in the third quarter increased by 51.6% year-over-year, reaching $104 million. This reflects the success of our internationalization strategy."

 

"Thanks to changes in our revenue structure and cost optimization measures, our gross profit margin improved by 3.2 percentage points compared to the same period last year, reaching 27.2%."

 

"Despite rapid revenue growth, we have maintained stable operating expenses under US GAAP, demonstrating strong operational leverage." 

 

"We are also pleased to return value to shareholders by distributing the second cash dividend since our IPO and continuing our stock repurchase plan." 

 

"We will actively pursue development opportunities to achieve sustainable profit growth and deliver higher returns to shareholders." 

 

On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
Ahead of the Formula 1 race in Madrid, 67 Spanish and international public-health, medical and consumer organizations have sent an open letter to F1 President and CEO Stefano Domenicali calling for an end to sponsorships linked to the tobacco and nicotine industry, including nicotine pouches, vaping products and heated tobacco. The letter focuses on Philip Morris International’s ZYN partnership with Ferrari and British American Tobacco’s long-running partnership with McLaren and exposure for VELO. The campaign follows a March letter in which more than 160 organizations worldwide made a similar request to Formula 1.
Sep.10
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22